Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Conditions

• Community-acquired Pneumonia, Influenza, COVID-19

Interventions

• DRUG: Ceftriaxone
• DRUG: Moxifloxacin or Levofloxacin
• DRUG: Piperacillin-tazobactam
• DRUG: Ceftaroline
• DRUG: Amoxicillin-clavulanate
• DRUG: Standard course macrolide
• DRUG: Extended course macrolide
• OTHER: No systemic corticosteroid
• DRUG: Fixed-duration Hydrocortisone
• DRUG: Shock-dependent hydrocortisone
• DRUG: Fixed-duration higher dose Hydrocortisone
• OTHER: No antiviral agent for influenza
• DRUG: Five-days oseltamivir
• DRUG: Ten-days oseltamivir
• OTHER: No antiviral agent for COVID-19
• DRUG: Lopinavir / Ritonavir
• DRUG: Hydroxychloroquine
• DRUG: Hydroxychloroquine + lopinavir/ritonavir
• DRUG: Ivermectin
• OTHER: No immune modulation for COVID-19

Sponsor

UMC Utrecht

Collaborators

• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]